Oct 15, 2019
Recently there have been attempts by small-to-medium sized pharmaceutical companies to create in-house, integrated platform-DDD (PD3) capabilities. This strategy does not come without risks, but has quietly been implemented to increase drug candidate efficacy/safety and pipeline numbers. In some cases this has resulted in much-vaunted success, as epitomised by the Moderna IPO in late 2018.
Although the complexities of such efforts should not be underestimated, it is clear that the new PD3 business model is being adopted and utilised. We evaluate this new paradigm and discuss the common traits and themes of successful PD3 companies.
Original article by Dr Stephen Naylor and Dr Kirkwood A. Pritchard Jr
If you'd like to view the original article then follow the link below:
You can also download the original article pdf here:
For more information on Drug Discovery World, head to: